Routine buyback disclosure with no deviation from announced program. Monitor for any changes in repurchase pace or program extension, but no immediate trading catalyst.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyback program. From September 21-25, 2026, the company repurchased 1.205 million B shares for approximately DKK 310 million, bringing total repurchases under the program to 20.62 million shares (DKK 6.14 billion). This is a routine administrative update with no new material information.
Key Facts
- Total share repurchase program of up to DKK 15 billion over 12 months beginning February 4, 2026
- Under the May 6, 2026 sub-program, Novo Nordisk will repurchase B shares up to DKK 11.2 billion through February 1, 2027
- From September 21-25, 2026, repurchased 1,205,000 B shares at an average price of DKK 257.10 per share
- Cumulative repurchases under the program: 20,620,000 B shares for DKK 6,139,842,042
- Novo Nordisk holds 49,419,876 B shares as treasury shares, representing 1.1% of total share capital
- Total A and B shares outstanding: 4,465,000,000 including treasury shares
Financial Impact
Weekly repurchases of ~DKK 310 million; total program execution of DKK 6.14 billion out of DKK 15 billion authorized
Risk Factors
- No material risks identified in this filing
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006248 |
| Document: 0001171843-26-006248-index-headers.html | 0001171843-26-006248 |
| Document: 0001171843-26-006248-index.html | 0001171843-26-006248 |
| Document: 0001171843-26-006248.txt | 0001171843-26-006248 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 3d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $39.14 (+0.03%) |
Oct 26, 2026 4d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $39.14 (+1.22%) |
Oct 19, 2026 10d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $39.14 (+1.87%) |
Oct 13, 2026 16d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $39.14 (+2.84%) |
Oct 6, 2026 23d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $39.14 (+4.29%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $39.14 (+1.11%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $39.14 (+1.35%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $39.14 (−1.66%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $39.14 (−9.38%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $39.14 (−7.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers